Business Strategy:

Cytochroma’s strategy is to leverage its knowledge of chronic kidney disease (CKD) and proven talent to discover, develop and commercialize leading-edge therapies for the CKD market.
The key elements of this strategy are to:

• Leverage a strategic partnership with Mitsubishi Tanabe Pharma Corporation to develop and commercialize breakthrough products;
• Apply existing management expertise to develop, market and sell products for CKD
• Expand an established key opinion leader network in nephrology and vitamin D molecular physiology;
• Leverage existing expertise in vitamin D intellectual property;
• Develop and out-license additional product offerings; and
• In-license and/or acquire new products.